Literature DB >> 11337545

L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations.

P L Jager1, H J Groen, A van der Leest, J W van Putten, R M Pieterman, E G de Vries, D A Piers.   

Abstract

UNLABELLED: L-3-[123I]iodo-alpha-methyl-tyrosine (IMT) is a modified amino acid that is avidly taken up by many tumors. Uptake is based on the increased transmembrane transport of amino acids in malignancies. IMT is the only amino acid tracer suitable for SPECT. The aim of this study was to determine the feasibility of IMT SPECT in the detection, staging, and treatment evaluation of non-small cell lung cancer.
METHODS: We evaluated 44 IMT SPECT studies in 17 patients with histologically proven non-small cell lung cancer, stage III. IMT SPECT and planar imaging of the chest was performed before, 2 wk after, and 3 mo after 60 Gy radiotherapy. Staging was based on the findings of bronchoscopy, chest CT, mediastinoscopy, or explorative thoracotomy. After radiotherapy, CT and bronchoscopy were repeated to assess tumor response.
RESULTS: In 15 of 16 evaluable primary tumors, avid IMT uptake was present (sensitivity, 94%), with a mean (+/-SD) tumor-to-background ratio (T/B) of 2.95 +/- 0.78 (range, 1.7-4.9). In 12 of 14 patients (86%) with mediastinal involvement, IMT SPECT detected one or more mediastinal metastases. However, only 13 of 20 mediastinal metastases were detected in lesion analysis (lesion-based sensitivity, 65%). For lesions < 2 cm in diameter, sensitivity was 42%. FDG PET (available for 5 patients) detected more known and unknown lesions than did IMT SPECT. After radiotherapy, T/B had fallen to 1.84 +/- 0.29 (P < 0.001 vs. baseline), and 3 mo later to 1.61 +/- 0.41 (not statistically significant vs. second study). Considerable nonspecific uptake was found in irradiated normal lung tissue (mean ratio to nonirradiated tissue, 1.79 +/- 0.53), persisting for > 3 mo. No relationship was observed between various IMT uptake parameters and the presence of residual viable tumor tissue or survival.
CONCLUSION: IMT SPECT has a high sensitivity for the detection of primary non-small cell lung cancer. Although patient-based sensitivity in detecting mediastinal spread was adequate, sensitivity for individual lesions, especially for small metastases (<2 cm in diameter) was too low to be clinically helpful. Radiotherapy caused considerable nonspecific IMT uptake, which also limits applicability in evaluating the results of treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337545

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

Review 2.  Weaving single photon imaging into new drug development.

Authors:  P David Mozley
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

3.  Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Authors:  Kyoichi Kaira; Tetsuya Higuchi; Ichiro Naruse; Yukiko Arisaka; Azusa Tokue; Bolag Altan; Satoshi Suda; Akira Mogi; Kimihiro Shimizu; Noriaki Sunaga; Takeshi Hisada; Shigehisa Kitano; Hideru Obinata; Takehiko Yokobori; Keita Mori; Masahiko Nishiyama; Yoshihito Tsushima; Takayuki Asao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-21       Impact factor: 9.236

4.  A systemic review of PET and biology in lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Noriaki Sunaga; Tamotsu Ishizuka; Kimihiro Shimizu; Nobuyuki Yamamoto
Journal:  Am J Transl Res       Date:  2011-07-27       Impact factor: 4.060

5.  Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer.

Authors:  Michail Plotkin; Reinhard Wurm; Julia Eisenacher; Katarzyna Szerewicz; Roger Michel; Lorenz Schlenger; Maciej Pech; Timm Denecke; David Kuczer; Annet Bischoff; Roland Felix; Holger Amthauer
Journal:  Eur Radiol       Date:  2005-06-28       Impact factor: 5.315

Review 6.  Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.

Authors:  Noboru Oriuchi; Hideki Endoh; Kyoichi Kaira
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.